A Phase 1 interventional study of BMS-986177 and Matched Placebo in Thrombosis, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-06-01.
Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Other
Access the safety, tolerability, and pharmacokinetics of BMS-986177 in healthy Japanese participants after multiple doses are administered.
1,506 studies on the registry are indexed under Thrombosis; 238 are open to participants now.
This study's enrollment of 33 is below the median of 106 across 849 interventional studies indexed under Thrombosis.
Browse Thrombosis studies →Bristol-Myers Squibb is the lead sponsor of 1,538 studies on the registry; 116 are open to participants now.
Of its 429 completed or terminated interventional studies of FDA-regulated products, 223 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Other protocol defined inclusion and exclusion criteria apply
Receive 50 mg BMS-986177 once daily or placebo
Drug: BMS-986177 · Other: Matched Placebo
Receive 200 mg BMS-986177 once daily or placebo
Drug: BMS-986177 · Other: Matched Placebo
Receive 500 mg BMS-986177 once daily or placebo
Drug: BMS-986177 · Other: Matched Placebo
Oral Suspension
Oral Suspension
Occurrence of Death
Measured by investigator assessment
Time frame: 30 days after last dose
Incidence of Serious Adverse Events (SAEs)
Measured by investigator assessment
Time frame: 30 days after last dose
Incidence of Adverse Events (AEs) Leading to Discontinuation of Study Therapy
Measured by investigator assessment
Time frame: 17 days
Incidence of Adverse Events (AEs) Resulting in Clinically Significant Bleeding
Measured by investigator assessment
Time frame: 17 days
Changes in Vital Signs (heart rate, systolic blood pressure, diastolic blood pressure, respiration rate, and temperature)
Measured by investigator assessment
Time frame: 17 days
Change from baseline in electrocardiogram findings (ECGs)
Measured by investigator assessment
Time frame: 17 days
This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bristol-Myers Squibb